News

Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker

Mar 11, 2024

We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA.

One of the abstracts is on the prognostic value of serum TK1 protein levels in Diffuse large B cell lymphoma (DLBCL) patients treated with a combination therapy called R-CHOP.
Below is the link for the full abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/1871
 
The other abstract is on serum TK1 protein concentrations as a predictive marker for castration resistance in metastatic prostate cancer.
Below is the link for the abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/11593

Further strengthening partnerships in Southeast Asia

May 29, 2026 |

In the beginning of May, IDL Diagnostics team visited our distributors in Indonesia and the Philippines as part of our ongoing efforts to strengthen local partnerships and stay closely connected to our markets. During our time in Jakarta, we had an in-depth discussion...

read more

Gustav Sten appointed CEO of IDL Diagnostics

May 19, 2026 |

IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the position on May 28, immediately following the Annual General Meeting, succeeding Anders Hultman.  Gustav Sten...

read more